2019
DOI: 10.1007/s11094-019-02005-z
|View full text |Cite
|
Sign up to set email alerts
|

Subvisible Particulate Matter in Therapeutic Protein Injections

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 18 publications
0
4
0
Order By: Relevance
“…The close agreement between the two curves confirms the reliability of the LO measurement. improve the accuracy in particle sizing by Light Obscuration measurements in several fields [5,6].…”
Section: Jinst 19 P04035mentioning
confidence: 99%
See 1 more Smart Citation
“…The close agreement between the two curves confirms the reliability of the LO measurement. improve the accuracy in particle sizing by Light Obscuration measurements in several fields [5,6].…”
Section: Jinst 19 P04035mentioning
confidence: 99%
“…Additionally, they are fast, easy to use, and can be used in situ or with minimal sample preparation. Therefore, they are suitable for real-time monitoring and process control applications [5,6]. They provide results within seconds, which is crucial for industrial use, including pharmaceuticals and electronics applications.…”
Section: Introductionmentioning
confidence: 99%
“…Denatured proteins or proteins that maintain a structurally altered conformation are more prone to protein aggregation. , The aggregated proteins can form a distribution of particle ensembles from a nanometer to micrometer size . Of particular concern are subvisible particles (SVPs) with dimensions approximately between 1 and 100 μm because of the increased scrutiny from regulatory agencies such as the U.S. Food and Drug Administration. These particles may increase the risk of immunogenicity relative to the same monomeric protein, as demonstrated by various in vitro and animal models. Whether SVP-mediated immunogenicity occurs or not seems to depend on the size and concentration of aggregates, the stress condition used to generate the aggregates, the protein itself, and the model used in the study (e.g., in vitro or mouse-based models). The relationship between these studies and immunogenicity in the clinic remains poorly understood.…”
Section: Introductionmentioning
confidence: 99%
“…The relationship between these studies and immunogenicity in the clinic remains poorly understood. It is also critical to note that the amount of aggregates/SVPs used in such studies is typically much higher than what is normally found in commercial biotherapeutic products, which are expected to comply with limits set in the United States and European Pharmacopeias. , Currently, there are safe, marketed products that were approved prior to the routine monitoring and control of SVPs. Nevertheless, there is a need to better understand the subvisible particle (SVP) formation to more effectively identify and disrupt potential particle formation pathways to ensure product quality, safety, and regulatory expectations …”
Section: Introductionmentioning
confidence: 99%